The advantages of being a privately owned or publicly listed pharma company continues to polarise opinion. A key consideration in this debate is the influence of ownership structure on company evolution and growth.
While private, smaller pharma companies are thought to be more agile, publicly listed companies are considered to have more scaling opportunities. Our analysis reveals a deeper complexity.
In this white paper, we discuss the benefits of each ownership structure, and evaluate three hypotheses exploring how ownership structure influences R&D and commercial performance.
There is no one-size-fits-all approach, and companies with different ownership structures can learn from one another to craft R&D and commercial strategies to best suit their unique situation.
To learn more, use the button above to read the full report.